《星岛》记者 秦亦 深圳报道 近期，创尔生物（NQ:831187）发布公告，宣布终止北交所上市辅导备案，意味着该公司推进三年之久 的IPO之路正式折戟，一场筹备已久的资本市场冲刺最终未能如愿。 ▲创尔生物终止上市辅导。 创尔生物主要产品为医疗器械类和生物护肤类，在医疗器械方面，该公司已掌握生物医用级活性胶原大 规模无菌提取制备技术，拥有2个Ⅲ类及2个Ⅱ类医疗器械注册证。2017-2019年，公司胶原类产品在我 国医药级胶原市场的市场份额分别为3.04%、3.40%和5.23%。 创尔生物并未在公告中披露股东股权冻结的细节，但据《星岛》了解，这与其二股东丁玉梅有直接关 联。根据创尔生物2025年半年报显示，丁玉梅持有该公司365.36万股，持股比例4.30%，成为第二大股 东。不过，这部分股权已悉数被司法冻结，无任何可流通空间。 事实上，创尔生物的上市之路并非一帆风顺，2020年该公司曾冲击科创板，2021年撤回上市申请材料后 转向北交所，如今却因一桩股权隐患再度停摆。 | | | | | | | | | 期末 | 单位:股 | | --- | --- | --- | --- | --- | --- | --- ...

Core Insights - The "Qihang·2025 Financial Summit" was successfully held in Beijing, focusing on "New Starting Point, New Momentum, New Journey," gathering hundreds of leaders and guests from regulatory bodies, industry associations, financial institutions, listed companies, and media [1] - The "Jizhi Award" was announced, with Juzhi Biotechnology winning the "Outstanding Growth Enterprise" award, aimed at setting high-quality development benchmarks and guiding listed companies to focus on their main business and continuous innovation [2][3] Company Performance - Juzhi Biotechnology demonstrated strong growth resilience in a sluggish market, achieving a revenue of 3.113 billion yuan in the first half of 2025, a year-on-year increase of 22.52%, and a net profit of 1.182 billion yuan, up 20.23% [4] - The company's main business focuses on professional skincare products and health foods, with professional skincare products accounting for over 99% of its core revenue [4] Brand Performance - The flagship brand, Kefu Mei, generated 2.54 billion yuan in revenue in the first half of 2025, a 22.7% increase, representing 81.7% of total revenue, with key products performing well in major sales events [5] - The Keli Jin brand also showed strong performance with a revenue of 503 million yuan, up 26.9%, and its star product ranked in the top 4 of the Tmall sales list for facial masks [5] Future Outlook - Juzhi Biotechnology plans to continue focusing on its main business, enhancing innovation, strengthening its omnichannel layout, and expanding into medical aesthetics and overseas markets to contribute to the high-quality development of the biological skincare industry [5]

Core Insights - Shenzhou Holdings' subsidiary, KJ, signed strategic cooperation agreements with four industry leaders in various sectors, indicating a strong commitment to enhancing smart supply chain solutions [1] Group 1: Strategic Partnerships - KJ has partnered with Lenovo Zhixiang, Jianmin Pharmaceutical, Zhenyan Biotechnology, and Heidi Garden, representing sectors such as office printing, healthcare, skincare, and horticulture [1] - The collaboration aims to provide customized smart supply chain solutions tailored to the specific needs and characteristics of each industry [1] Group 2: Company Expertise - Shenzhou Holdings emphasized that KJ's extensive industry experience and deep technological foundation are key factors that ensure the reliability of these partnerships [1]